Yüklüyor......
Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy
MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuva...
Kaydedildi:
| Yayımlandı: | Medchemcomm |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Royal Society of Chemistry
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6991171/ https://ncbi.nlm.nih.gov/pubmed/32133105 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1039/c9md00254e |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|